Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2025
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Public Offering Price: $1.00 per share.
- Firm Shares: 25,000,000 shares sold at $0.9425 per share (net of discount).
- Underwriting Discount: $0.0575 per share.
- Over-Allotment Option: 30-day option to purchase up to 3,750,000 additional shares.
- Gross Proceeds (Firm): $25,000,000.
- Gross Proceeds (With Full Option): $28,750,000.
- Reimbursable Expenses: Up to $100,000 for legal fees and other expenses.
- Underwriters: Canaccord Genuity LLC and BTIG, LLC (Joint Bookrunners).
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. The sale of the Firm Shares is expected to close on or about September 11, 2025, subject to customary closing conditions. This transaction will increase the company's cash position upon closing.
Guidance, Outlook, and Risks
Management Commentary: The offering was made pursuant to an existing shelf registration statement (Form S-3) filed in November 2022. Press releases announcing the commencement and pricing of the offering were issued on September 9 and September 10, 2025, respectively.
Risks and Contingencies:
- The transaction is subject to customary closing conditions.
- The Underwriting Agreement contains customary representations, warranties, and covenants.
- The Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the offering (expected September 11, 2025).
- Confirm whether the underwriters exercise the 3,750,000 share over-allotment option.
- Review the final prospectus supplement for updated use of proceeds.
- Check subsequent filings for the actual net proceeds received after deducting all expenses.
- Monitor the impact of the new share issuance on existing shareholder dilution.